Team:Rochester/Description

UR igem wiki

Description

  • Our project
  • We sought to create a novel, noninvasive diagnostic for endometriosis using menstrual effluent. Endometriosis is a chronic disease that causes aberrant endometrial-like tissue growth outside of the uterine cavity. It affects more than 200 million women worldwide and can lead to severe symptoms impacting reproductive health (Mutter, 2014). Currently, there are diagnostic methods available except for exploratory surgery (Biacchardi et al., 2011). Our wet lab team selected biomarkers for endometriosis in menstrual effluent and collaborated with expert physicians and researchers in the field of endometriosis to create lateral flow assays that can both qualitatively and quantitatively measure the presence of these biomarkers in menstrual effluent. This work was supported by the efforts of the modeling team, who created a predictive model to predict the likelihood that a patient has endometriosis based on demographic data and clinical symptoms. We incorporated this model into a software that clinicians can use to assess patient endometriosis risks. Additionally, our hardware team created a menstrual cup best suited for the collection of menstrual effluent and the comfort of endometriosis patients, and designed inexpensive laboratory equipment for clinics without easy laboratory access. Together, we were able to create a simple diagnostic for endometriosis that can be employed in a variety of clinical settings and used to resolve the gap of knowledge and raise awareness for female reproductive healthcare.

  • Subteams
  • Clear and Concise Description of Project
  • We sought to create a novel, noninvasive diagnostic for endometriosis using menstrual effluent. Endometriosis is a chronic disease that causes endometrial-like tissue growth outside of the uterine cavity. It affects more than 200 million women worldwide and can lead to severe symptoms impacting reproductive health (Mutter, 2014). Currently, there are no diagnostic methods available except for exploratory surgery (Biacchardi et al., 2011). Our team selected biomarkers for endometriosis in menstrual effluent and collaborated with expert physicians and researchers in the field of endometriosis to create lateral flow assays that can both qualitatively and quantitatively measure the presence of these biomarkers in menstrual effluent. We supported this work by creating an ordinary differential equations model to determine lateral flow assay parameters as well as a predictive model to determine if a patient has endometriosis based clinical symptoms. We incorporated the clinical predictive model into a software that clinicians can use to assess patients’ endometriosis risk. Additionally, we created a menstrual cup best suited for the collection of menstrual effluent and the comfort of endometriosis patients, and designed inexpensive laboratory equipment for clinics without easy laboratory access. Together, we were able to create a simple diagnostic for endometriosis that can be employed in a variety of clinical settings and used to resolve the gap of knowledge and raise awareness for female reproductive healthcare.

  • Application of Synthetic Biology
  • Producing Antibodies in Escherichia coli

    Our project makes use of synthetic biology by synthesizing proteins and antibodies through the creation of genetically modified organisms. The use of synthetic biology in producing materials is valuable because of its customizability and ease-of-use, which are principles that are integral to our project design. When creating our test, we found several important biomarkers for endometriosis that we believe to be critical in accurately predicting and diagnosing the disease. Immunoassays provided the best approach for the sensitive detection of our desired biomarkers, but as a first year team, we were worried about the high cost of using antibodies. As such, genetically engineering organisms to produce our required antibodies would help lower the cost of an immunoassay design for both ourselves and future iGEM teams. Previous literature research has shown the efficacy of using a specially engineered E. coli strain, SHuffle, for the production of antibodies. This strain has an oxidative cytoplasm and additional chaperone proteins that allows for proper folding and disulfide bond formation in full length immunoglobulin proteins (Lobstein et al., 2012). Our team created BioBricks for the variable and constant regions of a therapeutic antibody used in our design, Siltuximab, including a mutated constant chain for efficient use in E. coli SHuffle. This mutated constant region will be available for use by future iGEM teams who wish to produce their own antibody by combining our constant region BioBrick with their desired variable chain region via standard assembly for efficient production in E. coli SHuffle. This rapid, inexpensive method of antibody production will allow not only for immunoassay development for iGEM teams but also lays a foundation for the production of promising immunotherapy methods for the treatment of endometriosis and other chronic conditions.

    Therapeutic Estrogen Response Elements

    Our team hopes to create a therapeutic sensor for estrogen levels in endometriosis patients. This goal will be completed by designing a gene circuit that becomes active at elevated levels of estrogen to produce a reporter protein which can indicate to the patient the recommended dosage of hormone-targeting drugs. This gene circuit will build off of the work of the 2016 MIT Team, who worked on creating a promoter that could be induced by the binding of an estrogen receptor to estrogen response elements (EREs). EREs are short sequences of DNA preceding promoters which are activated when bound to by estrogen receptors (which translocate to the nucleus to promote transcription when activated by estrogen). We hope to improve the design of their circuit by altering the promoter to only respond to clinically elevated levels of estrogen and using E. coli as a chassis organism rather than human cells. The use of E. coli will make this gene circuit more accessible to other iGEM teams and will also avoid the ethical issues of designing a system for therapeutic use in human cells. While we do not intend to create a hardware device for this gene circuit, we postulate that in the future, this system could be integrated with hardware to provide rapid results of elevated estrogen levels that recommend a medication dosage for management. This could be beneficial if used as a personal device for patients undergoing hormone therapy compared to standard laboratory blood tests.

  • Goals
  • Create reliable diagnostic tools for endometriosis

    Utilize designs that are compatible with endometriosis symptoms

    Further research into endometriosis therapeutics

    Design affordable and easy to use laboratory equipment

    Spread awareness of endometriosis and women’s reproductive health

    Incorporate feasibility, ethics and sustainability into project design

    Make our project, and other iGEM projects, accessible across languages and cultures

    Increase knowledge about synthetic biology and resources for iGEM teams

  • Inspiration for Our Project
  • The major inspiration for our project came from a recent research publication detailing the presence of biomarkers for endometriosis in menstrual effluent (Warren et al., 2018). Having a team member who had been diagnosed with endometriosis, we were shocked to learn about the lack of research and funding that were allocated to this chronic disease and wanted to improve the quality of care provided to endometriosis patients. Warren et al. not only exposed our team to endometriosis research and unique diagnostics methods, but also inspired us to approach this problem with synthetic biology principles.
    We were also inspired by a previous iGEM team, MIT 2016, who tried to detect endometriosis using newly characterized parts from mammalian synthetic biology. Their work demonstrated how synthetic gene circuits can be utilized to detect endometriosis biomarkers and inspired our team to not only build upon this work, but find new ways to utilize synthetic biology in endometriosis diagnostics.

  • Impact of COVID-19 on Our Project
  • COVID-19 forced our team to perform the work for the majority of our project online. With team members from different areas of the world, communication and organization became difficult. We also had to heavily rely on past research and published literature for developing our project rather than hands on lab research.
    However, despite the difficulties, the switch to online research provided new opportunities for collaboration between our sub-teams. Our modeling team provided critical information to our wet lab team regarding the selection of materials and set up of our lateral flow assay. Our hardware team was also able to recognize the difficulties of having limited access to materials and were inspired to create build-it-yourself centrifuge to resolve this issue for teams, clinics, and laboratories across the world. Furthermore, all in person activities were cancelled but we were still able to connect and partner with organizations and foundations that support and actively engage in endometriosis. While our team faced setbacks due to COVID-19, we also took advantage of unexpected opportunities that shaped our project goals.

    References

    Biacchiardi, C. P., Piane, L. D., Camanni, M., Deltetto, F., Delpiano, E. M., Marchino, G. L., Gennarelli, G., & Revelli, A. (2011). Laparoscopic stripping of endometriomas negatively affects ovarian follicular reserve even if performed by experienced surgeons. Reproductive BioMedicine Online, 23(6), 740–746. https://doi.org/10.1016/j.rbmo.2011.07.014

    Lobstein, J., Emrich, C. A., Jeans, C., Faulkner, M., Riggs, P., & Berkmen, M. (2012). SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microbial Cell Factories, 11, 56. https://doi.org/10.1186/1475-2859-11-56

    Mutter, G. L. (2014). Endometriosis. In Pathology of the Female Reproductive Tract (pp. 487–508).

    Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., Taron, C. H., DeLisa, M. P., & Berkmen, M. (2015). Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nature Communications, 6(1), 8072. https://doi.org/10.1038/ncomms9072